Recent progress in dendrimer-based nanocarriers

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 23, Issue 6, 2006, Pages 437-495

  Bai, Shuhua ^a   Thomas, Chandan ^a   Rawat, Amit ^a   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Carrier system; Conjugate; Dendrimer; Drug delivery; Encapsulation; Imaging and diagnostic agent

Indexed keywords

ANTINEOPLASTIC AGENT; ARTEMETHER; BORON; CETUXIMAB; CHLOROQUINE; CHONDROITIN 4 SULFATE; CISPLATIN; CYCLODEXTRIN; DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GADOMER 17; INDOMETACIN; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; MACROGOL 2000; MACROGOL 5000; MACROGOL 750; METHOTREXATE; NANOCARRIER; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYAMIDOAMINE; POLYETHYLENEGLYCOL METHYL ETHER; POLYLYSINE; POLYMER; POLYPROPYLENEIMINE; STARBURST; SUPERFECT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIVAGEL;

ANALYZER; ARTHRITIS; BIOASSAY; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOENGINEERING; BIOMIMETICS; BRAIN TUMOR; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED DRUG RELEASE; COVALENT BOND; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA TRANSFECTION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; ELECTRICITY; ERYTHROCYTE; HEART DISEASE; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; IC 50; IMMUNOGENICITY; MAXIMUM PLASMA CONCENTRATION; MICELLE; MOLECULAR SIZE; MOLECULAR WEIGHT; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RETICULOENDOTHELIAL SYSTEM; REVIEW; SLOW DRUG RELEASE; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 34147119610     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v23.i6.10     Document Type: Review

References (149)

1. Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy. J Surg Res. 1964;4:139-42.
2. Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res. 2006;23:1-30.
3. Gupta U, Agashe HB, Asthana A, Jain NK. Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules. 2006;7:649-58.
4. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005;10:35-43.
5. Langereis S, de Lussanet QG, van Genderen MH, Meijer EW, Beets-Tan RG, Griffioen AW, van Engelshoven JM, Backes WH. Evaluation of Gd(III)DTPA- terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed. 2006;19:133-41.
6. Kobayashi H, Brechbiel MW. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev. 2005;57:2271-86.
7. Dear JW, Kobayashi H, Jo SK, Holly MK, Hu X, Yuen PS, Brechbiel MW, Star RA. Dendrimer-enhanced MRI as a diagnostic and prognostic biomarker of sepsis-induced acute renal failure in aged mice. Kidney Int. 2005;67:2159-67.
8. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. A new class of polymer:starburst-dendritic macromolecules. Polym J. 1985;17:117-32.
9. Dhanikula RS, Hildgen P. Synthesis and evaluation of novel dendrimers with a hydrophilic interior as nanocarriers for drug delivery. Bioconjug Chem. 2006;17:29-41.
10. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 2001;6:427-36.
11. Kobayashi H, Brechbiel MW. Dendrimer-based nanosized MRI contrast agents. Curr Pharm Biotechnol. 2004;5:539-49.
12. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev. 2005;57:2106-29.
13. Morawetz H, Ed. Polymers: the origin and growth of a science. 2 ed. Mineola, NY: Dover, 1985.
14. Al-Jamal KT, Ramaswamy C, Florence AT. Supramolecular structures from dendrons and dendrimers. Adv Drug Deliv Rev. 2005;57:2238-70.
15. Buhleier E, Wehner W, Vogtle F. Cascade- and "nonskid-chain- like" syntheses of molecular cavity topologies. Synthesis. 1978;1:155-8.
16. Tomalia DA. Dendrimer molecules. Sci Am. 1995;272:62-6.
17. Sadler K, Tam JP. Peptide dendrimers: applications and synthesis. J Biotechnol. 2002;90:195-229.
18. Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol. 2002;6:466-71.
19. Twyman LJ, King AS, Martin IK. Catalysis inside dendrimers. Chem Soc Rev. 2002;31:69-82.
20. Haensler J, Szoka FC Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem. 1993;4:372-9.
21. Lee CC, MacKay JA, Frechet JM, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol. 2005;23:1517-26.
22. Ambade AV, Savariar EN, Thayumanavan S. Dendrimeric micelles for controlled drug release and targeted delivery. Mol Pharm. 2005;2:264-72.
23. Newkome G, Young J, Baker G, Potter R, Audoly L, Cooper D, Weis C, Morris K, Johnson CJ. Cascade polymers: pH dependence of hydrodynamic radii of acid terminated dendrimers. Macromolecules. 1993;26:2394-6.
24. Sideratou A, Tsiouvas D, Paleos C. Quarternized poly(propylene imine) dendrimersas novel pH sensitive controlled release system. Langmuir. 2000;16:1766-9.
25. Roy R, Baek MG. Glycodendrimers: novel glycotope isosteres unmasking sugar coding. Case study with T-antigen markers from breast cancer MUC1 glycoprotein. J Biotechnol. 2002;90:291-309.
26. Bezouska K. Design, functional evaluation and biomedical applications of carbohydrate dendrimers (glycodendrimers). J Biotechnol. 2002;90:269-90.
27. Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. J Control Release. 2001;73:401-16.
28. Sun C, Wirsching P, Janda KD. Syntheses of dendritic linkers containing chlorambucil residues for the preparation of antibody-multidrug immunoconjugates. Bioorg Med Chem Lett. 2002;12:2213-5.
29. Tomalia DA. Birth of a new marcomolecular arthitecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Poly Sci. 2005;30:294-324.
30. Onitsuka K, Fujimoto M, Kitajima H, Ohshiro N, Takei F, Takahashi S. Convergent synthesis of platinum-acetylide dendrimers. Chemistry. 2004;10:6433-46.
31. Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochim Pol. 2001;48:199-208.
32. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005;57:2215-37.
33. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res. 2004;21:476-83.
34. Weil T, Wiesler UM, Herrmann A, Bauer R, Hofkens J, De Schryver FC, Mullen K. Polyphenylene dendrimers with different fluorescent chromophores asymmetrically distributed at the periphery. J Am Chem Soc. 2001;123:8101-8.
35. Uhrich KE, Boegeman S, Frechet JM, Turner SR. The solid-phase synthesis of dendrimtic polyamides. Polymer Bull. 1991;25:551-8.
36. Sakthivel T, Toth I, Florence AT. Synthesis and physicochemical properties of lipophilic polyamide dendrimers. Pharm Res. 1998;15:776-82.
37. Merrifield RB. Solid phase peptide sythesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85:2149.
38. Florence AT, Sakthivel T, Toth I. Oral uptake and translocation of a polylysine dendrimer with a lipid surface. J Control Release. 2000;65:253-9.
39. Jensen AW, Maru BS, Zhang X, Mohanty DK, Fahlman BD, Swanson DR, Tomalia DA. Preparation of fullerene-shell dendrimer-core nanoconjugates. Nano Lett. 2005;5:1171-3.
40. Khopade AJ, Caruso F, Tripathi P, Nagaich S, Jain NK. Effect of dendrimer on entrapment and release of bioactive from liposomes. Int J Pharm. 2002;232:157-62.
41. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mule J, Baker JR, Jr. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res. 2002;19:1310-6.
42. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147-62.
43. Kono K, Liu M, Frechet JM. Design of dendritic macromolecules containing folate or methotrexate residues. Bioconjug Chem. 1999;10:1115-21.
44. Sakthivel T, Florence AT. Dendrimers and dendrons: facets of pharmaceutical nanotechnology. Drug Deliv Tech. 2003;3:50-6.
45. Ihre HR, Padilla De Jesus OL, Szoka FC Jr., Frechet JM. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug Chem. 2002;13:443-52.
46. Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown NB, D'Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm. 2003;252:263-6.
47. Liu M, Kono K, Frechet JM. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release. 2000;65:121-31.
48. Pan G, Lemmouchi Y, Akala EO, Bakare O. Studies on PEGylated and drug-loaded PAMAM dendrimers. J Bioact Compat Polym. 2005;20:113-28.
49. Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem. 2000;11:910-7.
50. D'Emanuele A, Attwood D. Dendrimer-drug interactions. Adv Drug Deliv Rev. 2005;57:2147-62.
51. Haba Y, Harada A, Takagishi T, Kono K. Synthesis of biocompatible dendrimers with a peripheral network formed by linking of polymerizable groups. Polymer. 2005;46:1813-20.
52. Yang H, Morris JJ, Lopina ST. Polyethylene glycol-polyamidoamine dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J Colloid Interface Sci. 2004;273:148-54.
53. Bhadra D, Bhadra S, Jain S, Jain NK. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm. 2003;257:111-24.
54. Bhadra D, Bhadra S, Jain NK. Pegylated lysine based copolymeric dendritic micelles for solubilization and delivery of artemether. J Pharm Sci. 2005;8:467-82.
55. Lapatsanis L, Milias G, Froussios K, Kolovos M. Synthesis of N-2,2,2-(Trichloroethoxycarbonyl)-1-amino acids and N-(-9- Fluorenylmethoxycarbonyl)-1-amino acids involving succinimidoxy anion as a leaving group in amino acid protection. Synthesis. 1983:671-83.
56. Bhadra D, Bhadra S, Jain NK. PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate. Pharm Res. 2006;23:623-33.
57. Tansey W, Ke S, Cao XY, Pasuelo MJ, Wallace S, Li C. Synthesis and characterization of branched poly(L-glutamic acid) as a biodegradable drug carrier. J Control Release. 2004;94:39-51.
58. El-Sayed M, Ginski M, Rhodes C, Ghandehari H. Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J Control Release. 2002;81:355-65.
59. Jevprasesphant R, Penny J, Attwood D, McKeown NB, D'Emanuele A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res. 2003;20:1543-50.
60. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release. 2000;65:133-48.
61. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res. 1996;30:53-65.
62. Brazeau GA, Attia S, Poxon S, Hughes JA. In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery. Pharm Res. 1998;15:680-4.
63. Yoo H, Juliano RL. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res. 2000;28:4225-31.
64. Hecht S, Frechet JM. Dendritic encapsulation of function: applying nature's site isolation principle from biomimetics to materials science. Angew Chem Int Ed Engl. 2001;40:74-91.
65. Singh P, Moll F, 3rd, Lin SH, Ferzli C, Yu KS, Koski RK, Saul RG, Cronin P. Starburst dendrimers: enhanced performance and flexibility for immunoassays. Clin Chem. 1994;40:1845-9.
66. Kofoed J, Reymond JL. Dendrimers as artificial enzymes. Curr Opin Chem Biol. 2005;9:656-64.
67. Delort E, Darbre T, Reymond JL. A strong positive dendritic effect in a peptide dendrimer-catalyzed ester hydrolysis reaction. J Am Chem Soc. 2004;126:15642-3.
68. Drake MD, Bright FV, Detty MR. Dendrimeric organochalcogen catalysts for the activation of hydrogen peroxide: origins of the "dendrimer effect" with catalysts terminating in phenylseleno groups. J Am Chem Soc. 2003;125:12558-66.
69. Sontjens SH, Nettles DL, Carnahan MA, Setton LA, Grinstaff MW. Biodendrimer-based hydrogel scaffolds for cartilage tissue repair. Biomacromolecules. 2006;7:310-6.
70. Neerman MF, Zhang W, Parrish AR, Simanek EE. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int J Pharm. 2004;281:129-32.
71. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev. 2005;57:2177-202.
72. Yoo H, Sazani P, Juliano RL. PAMAM dendrimers as delivery agents for antisense oligonucleotides. Pharm Res. 1999;16:1799-804.
73. Wang Y, Bai Y, Price C, Boros P, Qin L, Bielinska AU, Kukowska-Latallo JF, Baker JR, Jr., Bromberg JS. Combination of electroporation and DNA/dendrimer complexes enhances gene transfer into murine cardiac transplants. Am J Transplant. 2001;1:334-8.
74. Fu Y, Nitecki DE, Maltby D, Simon GH, Berejnoi K, Raatschen HJ, Yeh BM, Shames DM, Brasch RC. Dendritic iodinated contrast agents with PEG-cores for CT imaging: synthesis and preliminary characterization. Bioconjug Chem. 2006;17:1043-56.
75. Kobayashi H, Reijnders K, English S, Yordanov AT, Milenic DE, Sowers AL, Citrin D, Krishna MC, Waldmann TA, et al. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res. 2004;10:7712-20.
76. Pugh VJ, Hu QS, Pu L. The first dendrimer-based enantioselective fluorescent sensor for the recognition of chiral amino alcohols. Angew Chem Int Ed Engl. 2000;39:3638-41
77. Cloninger MJ. Biological applications of dendrimers. Curr Opin Chem Biol. 2002;6:742-8.
78. Devarakonda B, Hill RA, de Villiers MM. The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine. Int J Pharm. 2004;284:133-40.
79. Yiyun C, Tongwen X. Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem. 2005;40:1188-92.
80. Milhem OM, Myles C, McKeown NB, Attwood D, D'Emanuele A. Polyamidoamine Starburst dendrimers as solubility enhancers. Int J Pharm. 2000;197:239-41.
81. Devarakonda B, Hill RA, Liebenberg W, Brits M, de Villiers MM. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm. 2005;304:193-209.
82. Chauhan AS, Jain NK, Diwan PV, Khopade AJ. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target. 2004;12:575-83.
83. Chauhan AS, Sridevi S, Chalasani KB, Jain AK, Jain SK, Jain NK, Diwan PV. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release. 2003;90:335-43.
84. Yiyun C, Tongwen X, Rongqiang F. Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. Eur J Med Chem. 2005;40:1390-3.
85. Yiyun C, Tongwen X. Solubility of nicotinic acid in polyamidoamine dendrimer solutions. Eur J Med Chem. 2005;40:1384-9.
86. Asthana A, Chauhan AS, Diwan PV, Jain NK. Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS Pharm Sci Tech. 2005;6:E536-42.
87. Ooya T, Lee J, Park K. Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjug Chem. 2004;15:1221-9.
88. Kaanumalle LS, Nithyanandhan J, Pattabiraman M, Jayaraman N, Ramamurthy V. Water-soluble dendrimers as photochemical reaction media: chemical behavior of singlet and triplet radical pairs inside dendritic reaction cavities. J Am Chem Soc. 2004;126:8999-9006.
89. Namazi H, Adeli M. Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agents. Biomaterials. 2005;26:1175-83.
90. Wu H, Liu Z, Wang X, Zhao B, Zhang J, Li C. Preparation of hollow capsule-stabilized gold nanoparticles through the encapsulation of the dendrimer. J Colloid Interface Sci. 2006;302:142-8.
91. Kim JB, Choi JS, Nam K, Lee M, Park JS, Lee JK. Enhanced transfection of primary cortical cultures using arginine-grafted PAMAM dendrimer, PAMAM-Arg. J Control Release. 2006;114:110-7.
92. Kitchens KM, El-Sayed ME, Ghandehari H. Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv Drug Deliv Rev. 2005;57:2163-76.
93. Helin V, Gottikh M, Mishal Z, Subra F, Malvy C, Lavignon M. Uptake and intracellular distribution of oligonucleotides vectorized by a PAMAM dendrimer. Nucleosides Nucleotides. 1999;18:1721-2.
94. Goula D, Remy JS, Erbacher P, Wasowicz M, Levi G, Abdallah B, Demeneix BA. Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene Ther. 1998;5:712-7.
95. Goula D, Benoist C, Mantero S, Merlo G, Levi G, Demeneix BA. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther. 1998;5:1291-5.
96. Tang MX, Szoka FC. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther. 1997;4:823-32.
97. Marano RJ, Wimmer N, Kearns PS, Thomas BG, Toth I, Brankov M, Rakoczy PE. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res. 2004;79:525-35.
98. Marano RJ, Toth I, Wimmer N, Brankov M, Rakoczy PE. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther. 2005;12:1544-50.
99. Maruyama-Tabata H, Harada Y, Matsumura T, Satoh E, Cui F, Iwai M, Kita M, Hibi S, Imanishi J, et al. Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer. Gene Ther. 2000;7:53-60.
100. Balicki D, Reisfeld RA, Pertl U, Beutler E, Lode HN. Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma. Proc Natl Acad Sci U S A. 2000;97:11500-4.
101. Wang Y, Boros P, Liu J, Qin L, Bai Y, Bielinska AU, Kukowska-Latallo JF, Baker JR, Jr., Bromberg JS. DNA/dendrimer complexes mediate gene transfer into murine cardiac transplants ex vivo. Mol Ther. 2000;2:602-8.
102. Kabanov VA, Sergeyev VG, Pyshkina OA, Zinchenko AA, Zezin AB, Joosten JGH, Brackman J, Yoshikawa K. Interpolyelectrolyte complexes formed by DNA and astramol poly(propylene imine) dendrimers. Macromolecules. 2000;33:9587-93.
103. Bayele HK, Ramaswamy C, Wilderspin AF, Srai KS, Toth I, Florence AT. Protein transduction by lipidic peptide dendrimers. J Pharm Sci. 2006;95:1227-37.
104. Arima H, Kihara F, Hirayama F, Uekama K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins. Bioconjug Chem. 2001;12:476-84.
105. Sashiwa H, Yajima H, Aiba S. Synthesis of a chitosan-dendrimer hybrid and its biodegradation. Biomacromolecules. 2003;4:1244-9.
106. Bai S, Thomas C, Ahsan F. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low molecular weight heparin. J Pharm Sci. 2007; Feb 7; PMID: 17286291.
107. Kasai S, Nagasawa H, Shimamura M, Uto Y, Hori H. Design and synthesis of antiangiogenic/heparin-binding arginine dendrimer mimicking the surface of endostatin. Bioorg Med Chem Lett. 2002;12:951-4.
108. Azizkhan RG, Azizkhan JC, Zetter BR, Folkman J. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med. 1980;152:931-44.
109. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000;21:505-15.
110. Purohit G, Sakthivel T, Florence AT. Interaction of cationic partial dendrimers with charged and neutral liposomes. Int J Pharm. 2001;214:71-6.
111. Zhuo RX, Du B, Lu ZR. In vitro release of 5-fluorouracil with cyclic core dendritic polymer. J Control Release. 1999;57:249-57.
112. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs. 1999;10:767-76.
113. Patri AK, Kukowska-Latallo JF, Baker JR, Jr. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev. 2005;57:2203-14.
114. Choi Y, Baker JR, Jr. Targeting cancer cells with DNA-assembled dendrimers: a mix and match strategy for cancer. Cell Cycle. 2005;4:669-71.
115. Majoros IJ, Myc A, Thomas T, Mehta CB, Baker JR, Jr. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules. 2006;7:572-9.
116. Roy R, Baek MG, Rittenhouse-Olson K. Synthesis of N,N′- bis(acrylamido)acetic acid-based T-antigen glycodendrimers and their mouse monoclonal IgG antibody binding properties. J Am Chem Soc. 2001;123:1809-16.
117. Rendle PM, Seger A, Rodrigues J, Oldham NJ, Bott RR, Jones JB, Cowan MM, Davis BG. Glycodendriproteins: a synthetic glycoprotein mimic enzyme with branched sugar-display potently inhibits bacterial aggregation. J Am Chem Soc. 2004;126:4750-1.
118. Shaunak S, Thomas S, Gianasi E, Godwin A, Jones E, Teo I, Mireskandari K, Luthert P, Duncan R, et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol. 2004;22:977-84.
119. Yang H, Lopina ST. Penicillin V-conjugated PEG-PAMAM star polymers. J Biomater Sci Polym Ed. 2003;14:1043-56.
120. Sanchez-Sancho F, Perez-Inestrosa E, Suau R, Mayorga C, Torres MJ, Blanca M. Dendrimers as carrier protein mimetics for IgE antibody recognition. Synthesis and characterization of densely penicilloylated dendrimers. Bioconjug Chem. 2002;13:647-53.
121. Tam JP, Lu YA, Yang JL. Antimicrobial dendrimeric peptides. Eur J Biochem. 2002;269:923-32.
122. Yang H, Lopina ST. Extended release of a novel antidepressant, venlafaxine, based on anionic polyamidoamine dendrimers and poly(ethylene glycol)-containing semi-interpenetrating networks. J Biomed Mater Res A. 2005;72:107-14.
123. Wiwattanapatapee R, Lomlim L, Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release. 2003;88:1-9.
124. McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, Heery G, Paull JR, Matthews BR, Holan G. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm. 2005;2:312-8.
125. Mahor S, Rawat A, Gupta PN, Mishra V, Vyas SP. Proceeding of Annual Meeting and Exposition of Controlled Release Society; 2005. June 18-22; Florida, USA.
126. Zhang GD, Harada A, Nishiyama N, Jiang DL, Koyama H, Aida T, Kataoka K. Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer. J Control Release. 2003;93:141-50.
127. Khopade AJ, Khopade S, Jain NK. Development of hemoglobin aquasomes from spherical hydroxyapatite cores precipitated in the presence of half-generation poly(amidoamine) dendrimer. Int J Pharm. 2002;241:145-54.
128. Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA, Lauterbur PC. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med. 1994;31:1-8.
129. http://www.nobel.se/medicine/laureate/2003/press.html. 2003.
130. Kobayashi H, Brechbiel MW. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging. 2003;2:1-10.
131. Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. Magma. 2001;12:128-34.
132. Kobayashi H, Kawamoto S, Bernardo M, Brechbiel MW, Knopp MV, Choyke PL. Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging. J Control Release. 2006;111:343-51.
133. Kobayashi H, Jo SK, Kawamoto S, Yasuda H, Hu X, Knopp MV, Brechbiel MW, Choyke PL, Star RA. Polyamine dendrimer-based MRI contrast agents for functional kidney imaging to diagnose acute renal failure. J Magn Reson Imaging. 2004;20:512-8.
134. Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW. Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res. 2003;63:271-6.
135. Staatz G, Spuntrup E, Buecker A, Misselwitz B, Gunther RW. T1-weighted MR-lymphography after intramammary administration of Gadomer-17 in pigs. Rofo. 2002;74:29-32.
136. Fujimoto Y, Okuhata Y, Tyngi S, Namba Y, Oku N. Magnetic resonance lymphography of profundus lymph nodes with liposomal gadolinium- diethylenetriamine pentaacetic acid. Biol Pharm Bull. 2000;23:97-100.
137. Harika L, Weissleder R, Poss K, Zimmer C, Papisov MI, Brady TJ. MR lymphography with a lymphotropic T1-type MR contrast agent: Gd-DTPA-PGM. Magn Reson Med. 1995;33:88-92.
138. Choyke PL, Kobayashi H. Functional magnetic resonance imaging of the kidney using macromolecular contrast agents. Abdom Imaging. 2006;31:224-31.
139. Choyke PL, Austin HA, Frank JA, Girton ME, Diggs RL, Dwyer AJ, Miller L, Nussenblatt R, McFarland H, Simon T. Hydrated clearance of gadolinium-DTPA as a measurement of glomerular filtration rate. Kidney Int. 1992;41:1595-8.
140. Frank JA, Choyke PL, Austin HA, Girton ME. Functional MR of the kidney. Magn Reson Med. 1991;22:319-23.
141. Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest Radiol. 1997;32:748-54.
142. Kobayashi H, Kawamoto S, Saga T, Sato N, Ishimori T, Konishi J, Ono K, Togashi K, Brechbiel MW. Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. Bioconjug Chem. 2001;12:587-93.
143. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magma. 2001;12:104-13.
144. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4:623-6.
145. Le Berre V, Trevisiol E, Dagkessamanskaia A, Sokol S, Caminade AM, Majoral JP, Meunier B, Francois J. Dendrimeric coating of glass slides for sensitive DNA microarrays analysis. Nucleic Acids Res. 2003;31:e88.
146. Li Y, Cu YT, Luo D. Multiplexed detection of pathogen DNA with DNA-based fluorescence nanobarcodes. Nat Biotechnol. 2005;23:885-9.
147. Heeschen C, Goldmann BU, Langenbrink L, Matschuck G, Hamm CW. Evaluation of a rapid whole blood ELISA for quantification of troponin I in patients with acute chest pain. Clin Chem. 1999;45:1789-96.
148. Reber G, Bounameaux H, Perrier A, De Moerloose P. A new rapid point-of-care D-dimer enzyme-linked immunosorbent assay (Stratus CS D-dimer) for the exclusion of venous thromboembolism. Blood Coagul Fibrinolysis. 2004;15:435-8.
149. Tomalia DA, Brothers HM, 2nd, Piehler LT, Durst HD, Swanson DR. Partial shell-filled core-shell tecto(dendrimers): a strategy to surface differentiated nano-clefts and cusps. Proc Natl Acad Sci U S A. 2002;99:5081-7.